Pricing Log in Create free account

CytoMed Therapeutics Limited (GDTC) vs GT Biopharma, Inc. (GTBP)

CytoMed Therapeutics Limited and GT Biopharma, Inc. are both Biotechnology companies. CytoMed Therapeutics Limited is the larger, with a market value of $10.4M against $9.4M — 1.1× the size. CytoMed Therapeutics Limited has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. Across the 10 metrics below, GT Biopharma, Inc. leads on 6 and CytoMed Therapeutics Limited on 4.

Valuation

Metric GDTC GTBP Biotechnology median
P/E n/m 0.81 10.26
P/S n/m 121.89 9.18
P/B 0.55 2.05 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 482.71 8.98
Earnings yield (32.94%) 122.77% (34.89%)
Free cash flow yield (0.40%) (194.98%) (24.52%)

Profitability

Metric GDTC GTBP Biotechnology median
Gross margin 0.00% 41.67% 65.16%
Operating margin — 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 102.03% (50.12%)
Return on assets 0.00% (176.27%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GDTC GTBP Biotechnology median
Revenue growth (TTM) — (76.19%) 6.26%
EPS growth (last fiscal year) (68.75%) 3.75% 29.88%
Revenue growth, 5-year CAGR — 19.67% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GDTC GTBP Biotechnology median
Debt to equity 80.30 0.00 0.00
Current ratio 2.64 2.61 4.89
Net debt to EBITDA 0.86 0.56 1.01

Dividend

Metric GDTC GTBP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GDTC GTBP Biotechnology median
Market cap 10.41m 9.36m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack